Psychedelic Therapy for Wellness Studies Retrospectively

Status Active, not recruiting

Clinical Trial Summary

The overall aim of this study is to assess the efficacy psychedelics for improving measures of wellness using a retrospective, single period, cohort study

Clinical Trial Description

Previous research has largely focused on treating specific diagnostics groups such as depression, chronic pain, anxiety disorders with various approaches. With the significant overlap in symptomology with respect to diagnostic criteria and the presence of comorbidity, the results are challenging to extrapolate to real world applications. Therefore many authors have argued relying less on specific diagnoses, and instead focus on wellness, where symptom clusters or so called dimensions are explored independently. The WHO constitution states: "Health is a state of complete physical, mental and social well-being and not merely the absence of disease or infirmity." An important implication of this definition is that health is more than just the absence of disorders or disabilities. Health is a state of well-being in which an individual realizes his or her own abilities, can cope with the normal stresses of life, can work productively and is able to contribute to his or her community. Research Objective: In the current research investigators seek to measure the self-reported treatment effects of psychedelics (Psilocybin, 3,4-Methylenedioxymethamphetamine, N,N-Dimethyltryptamine, Lysergic Acid Diethylamide and Ketamine) for non recreational purposes (i.e., to self-medicate to ameliorate symptoms of suffering). Investigators will use a composite score of patient global perception, along with pain, function and mood scores as the measure of wellness, an approach to measurement which has not been done to date. Investigators follow previous work in this area, using a patient retrospective self-report study design, allowing for a safe way to develop further evidence in this area of care. Participants and Procedure: 50 non active military participants not under the care of Dr. Gupta will be recruited through word of mouth and advertising to self-identify as having used psychedelic medicine for non recreational purposes (Appendix B recruitment letter). In addition to demographic information, they will be asked to complete the PGIC and anxiety, mood, pain and disability subscales, PEG, HADS and DI, provide information on their past medical history, nature/indications for use, and adverse events. This data will be collected once per participant and they will be able to speak with a research associate if further clarification if necessary at anytime. Risks and Risk Mitigation: Participation in this study is voluntary and volunteers can withdraw consent at any time or skip any question they would prefer not to answer without having any effect on access to future medical care. Due to the nature of this study there are no additional associated risks. Patients can ask to be contacted by the research team should they wish to discuss any concerns, but will be apprised that this will breach their anonymity. The PI agree to maintain accurate and secure records. The spreadsheet generated from this data will be password protected and anonymized. Only the research team will have access to this data and no patients will be identifiable unless they provide contact information requesting follow up. Benefits and Military Significance: Outcomes of this project could potentially improve the quality of care for patients with various types of suffering by providing initial insights into these emerging treatments. The Canadian Forces specifically has considerably high rates of patients with comorbid pain and mental health issues. Therefore determining the impact on wellness could lead to further validation of treatments to improve quality of life, personal and occupational function. ;

Study Design

Related Conditions & MeSH terms

Well Aging

Clinical Trial Details

NCT number	NCT05469243
Study type	Observational
Source	Canadian Forces Health Services Centre Ottawa
Contact
Status	Active, not recruiting
Phase
Start date	July 19, 2022
Completion date	August 27, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05233813` - Active Body and Mind Intervention for Older Adults	N/A
Completed	`NCT05202652` - Evaluation of Anti-oxidant, Anti-aging and Wellbeing Effects of a Novel Nutraceutical Formulation (HealthSpan)	N/A
Recruiting	`NCT05544760` - CatchU: A Quantitative Multisensory Falls-Assessment Study	N/A
Completed	`NCT04378803` - Mindfulness Training for Seniors	N/A
Completed	`NCT04593433` - A 3-month Cycle of Virtual Guided Tours to Promote Health in Older Community Members in a Context of COVID-19 Induced Social Isolation: a Pilot Study	N/A
Completed	`NCT04913363` - The Emotional, Physical and Cognitive Benefits of Purposeful Green Space Activities on Seniors	N/A
Active, not recruiting	`NCT03962985` - Effects of Montreal Museum of Fine Arts Visits and Older Community Dwellers With a Precarious State	N/A
Recruiting	`NCT05120791` - Age Related Effects Consuming Phaeodactylum Tricornutum	N/A
Completed	`NCT05350046` - Development of Physical Activity Features for Ear-worn Devices	N/A
Completed	`NCT04570813` - Art'Health: Effects of Artistic and Participative Workshops at the MAMAC of Nice on the Health of Seniors	N/A
Completed	`NCT05046288` - Virtual Guided Tour of the MMFA for Prevention of Social Isolation	N/A
Not yet recruiting	`NCT04548115` - ARTISAN 2.0: Deconstructing the Integrative Efficacy of a Multimodal Art-based Intervention	N/A
Completed	`NCT05918289` - Improving Wellbeing in Older Adults: The Impact of an Active Aging Education Program in Pakistan	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.